Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | UBE2M | P61081 | 3/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30470218 | 1.00 | NPC1 (0.54) | NPC1RAB9ATP53ALDH1A1MAPT | |
| SCHEMBL24691197 | 0.83 | ALDH1A1 (0.64) | TP53ALDH1A1MAPTPOLBLMNA | |
| SCHEMBL30753156 | 0.82 | NPC1 (0.65) | NPC1RAB9ATP53ALDH1A1MAPT | |
| SCHEMBL24366873 | 0.79 | ALDH1A1 (0.40) | NPC1RAB9ATP53ALDH1A1LMNA | |
| SCHEMBL26185586 | 0.78 | NPC1 (0.40) | NPC1RAB9ATP53ALDH1A1MAPT | |
| SCHEMBL1745406 | 0.78 | NPC1 (0.62) | NPC1RAB9ATP53MAPTPOLB | |
| SCHEMBL24366681 | 0.77 | NPC1 (0.58) | NPC1RAB9ATP53ALDH1A1MAPT | |
| SCHEMBL30470893 | 0.77 | NPC1 (0.58) | NPC1RAB9ATP53ALDH1A1MAPT | |
| SCHEMBL30469758 | 0.77 | ALDH1A1 (0.39) | NPC1RAB9ATP53ALDH1A1LMNA | |
| SCHEMBL30470644 | 0.77 | ALDH1A1 (0.39) | NPC1RAB9ATP53ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NPC1 39/4885RAB9A 320/4885TP53 1097/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NPC1 39/4885RAB9A 320/4885TP53 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.